Down Syndrome to drive the Non Invasive Prenatal Testing Market

Date : May 28, 2021 Author : PMR Editorial Staff Category : Healthcare

The global non-invasive prenatal testing market will witness a CAGR of 10.7% in the next 10 years – Persistence Market Research (PMR).

An unborn child could be subject to mutation in chromosomes and genes, which, in turn, could increase risk pertaining to genetic abnormalities. This is evident from the fact that trisomy 21 ia amongst the common chromosomal abnormalities that affects close to 5K babies every single year in the US. This data has been released by the Children’s Hospital of Philadelphia. This calls for non-invasive prenatal testing, more so due to the fact that procedures like CVS (Chorionic Villus Sampling) and amniocentesis are invasive and expensive. Clinical benefits of non-invasive prenatal testing are absolutely no risk regarding miscarriage and budget-friendliness (as stated above).

The global non-invasive prenatal testing market will witness a CAGR of 10.7% in the next 10 years – Persistence Market Research (PMR).

An unborn child could be subject to mutation in chromosomes and genes, which, in turn, could increase risk pertaining to genetic abnormalities. This is evident from the fact that trisomy 21 ia amongst the common chromosomal abnormalities that affects close to 5K babies every single year in the US. This data has been released by the Children’s Hospital of Philadelphia. This calls for non-invasive prenatal testing, more so due to the fact that procedures like CVS (Chorionic Villus Sampling) and amniocentesis are invasive and expensive. Clinical benefits of non-invasive prenatal testing are absolutely no risk regarding miscarriage and budget-friendliness (as stated above).

Non-Invasive Prenatal Testing Market Report 2021-2028 emphasizes on the importance of non-invasive prenatal testing (NIPT), the factors driving the market along with the latitude and longitude of the nitty-gritties related therein. It has also highlighted facts published by SeraCare that in-vitro diagnostics manufacturers are collaborating with clinical testing laboratories and research organizations for determining SARS-CoV-2 infection’s interference on birth defects in the newborns and requirement for NIPT during the ongoing pandemic. This is COVID-19 Impact on Non-Invasive Prenatal Testing Market. On the other hand, there is no stoppage to research conducted like the one above. NIPT Market Size & Report by Persistence Market Research (PMR) has captured these essential facts and also provided insights regarding the same.

Non-Invasive Prenatal Testing Market Share, Size and Trends

Prenatal testing is finding its way through non-invasive tests due to economic and clinical advantages being offered. Several countries across the globe have started implementing policies wherein NIPT is now amongst the standard tests regarding prenatal screening. For instance – The Netherlands has declared non-invasive tests as the standard tests to conduct screening of the pregnant women therein.

Also, it’s a fact that economic and social factors in the current scenario have shifted the maternal age at childbearing. England-based Office for National Statistics (ONS) has published that as of the year 2017, mothers’ average age did increase to 30.5 years. As such, prevalence of numerous genetic complications and Down Syndrome has increased manifold. EUROCAT has stated that close to 8,320 babies all over the Europe suffered from Down Syndrome in the year 2019 alone. Non-Invasive Prenatal Testing Market Research Report by Persistence Market Research (PMR) delves deep into these anomalies.

Non-Invasive Prenatal Testing Market Segmentation

Non-Invasive Prenatal Testing Market 2027 By Type spans instruments and reagents & consumables. Out of these, reagents & consumables hold the largest market share due to new-fangled test kits being introduced on the continuous basis along with growing number of lab-based tests being performed. Plus, extensive research is being conducted regarding screening of the genetic disorders. On the developments front, QIAGEN and Natera, in the year 2019, did strategically partner with each other for developing cell-free DNA assays to be used on the former’s GeneReader NGS System.

Invitae Non-Invasive Prenatal Testing is capable of detecting fetal chromosomal abnormalities even as early as “10 weeks”. WGS (Whole-Genome Sequencing) is used for analysing cell-free DNA (cfDNA) for assessing if twin or singleton pregnancy is at risk for 3 common chromosomal disorders on 21st, 13th, and 18th chromosome.

Technology-wise, the non-invasive prenatal testing market constitutes microarray, next-generation sequencing, rolling circular amplification, and PCR. Out of these, next-generation sequencing dominates the market. Rolling circular amplification by PerkinElmer Inc. is expected to capture the major share of the market with cost-effectiveness and elimination of PCR.

Non-Invasive Prenatal Testing Market by End-user comprises clinical laboratories and hospitals. Clinical laboratories are holding the largest share due to innovative technology being incorporated.

Region-wise

North America leads from the front with growing incidences of Down Syndrome in the new-borns. Amongst the novel developments are Natera’s Panorama test, which is capable of differentiating between fetal and maternal DNA in chromosomes to be tested. In Europe, Illumina, Inc.’s Verse NIPT industry solution is amongst the well-known NGS-based tests. In the US, non invasive prenatal testing cost is close to US$ 500.

Non-invasive prenatal testing UK has cell-free DNA screening that is available through private healthcare providers since the year 2012. There is a maternal blood test involved therein. Majority of DNA comes from the mum and the rest from placenta of the baby.

The Asia-Pacific is expected to grow at the fastest rate in the NIPT market due to emerging economies like India gaining awareness about early diagnosis of the chromosomal disorders at the time of pregnancies. NIPT test cost in India is US$ 344.2 as of now. However, Thyrocare is planning to table the NIPT at US$ 110.14. As such, NIPT test in India is bound to turn out to be pretty affordable in the years to come. Non-invasive prenatal testing gender is done wherever detection of fetal sex is allowed. For instance – in India, it’s banned.

The key market participants profiled by PMR include:

  • Illumina, Inc.
  • YOURGENE HEALTH
  • Natera
  • PerkinElmer Inc.
  • Laboratory Corporation of America
  • Eurofins LifeCodexx GmbH